Medivir AB Series B | Balance Sheet

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
402
1,396
1,078
1,698
468
286
Total Accounts Receivable
34
306
82
54
13
13
Inventories
-
24
24
19
-
-
Other Current Assets
22
12
13
34
8
12
Total Current Assets
482
1,737
1,192
1,787
489
312
Net Property, Plant & Equipment
28
27
26
22
14
11
Long-Term Note Receivable
10
3
-
-
-
-
Intangible Assets
432
418
398
112
113
97
Total Assets
998
2,184
1,616
1,922
616
419
ST Debt & Current Portion LT Debt
-
40
-
-
-
Accounts Payable
29
41
37
57
34
Other Current Liabilities
74
121
98
132
68
Total Current Liabilities
103
201
135
189
102
Long-Term Debt
40
-
-
-
-
Deferred Taxes
43
-
31
1
-
Total Liabilities
145
201
166
189
102
Common Equity (Total)
853
1,983
1,450
1,733
514
Total Shareholders' Equity
853
1,983
1,450
1,733
514
Total Equity
853
1,983
1,450
1,733
514
Liabilities & Shareholders' Equity
998
2,184
1,616
1,922
616

About Medivir AB

View Profile
Address
Lunastigen 7
Huddinge AB 141 44
Sweden
Employees -
Website http://www.medivir.com
Updated 07/08/2019
Medivir AB engages in the development of pharmaceuticals products. It focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipeline such as remetinostat, birinapant, MV-818, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project.